Thanks to the new crown product sales and testing business volume growth, Mind Biological (002932) first half of the year results increased greatly. Matilda biological August 23 evening disclosure 2020 half-yearly report, the first half of the company achieved revenue of 361 million yuan, an increase of 253.98% year-on-year; net profit of 200 million yuan, an increase of 397.19% year-on-year; basic earnings per share of 3.01 yuan.
Mindray Bio said, foreign epidemic situation is still severe, the domestic epidemic can not be ignored, is expected to three quarters of the new crown product business is still larger, is expected to 2020 the first three quarters of the realization of the net profit increased by 513.33% year-on-year -665.93%.
Reagents and testing services revenue to support the performance
Half-yearly report shows that during the reporting period, Mind Biological realize sales revenue of 360 million yuan, an increase of 253.98%; realize the deduction of net profit of about 201 million yuan, an increase of 519.46%.
Mindray Bio summarized in the half-yearly report, in the first half of 2020, the new coronavirus epidemic outbreak, the company is located in Wuhan, a serious epidemic within the city, the first quarter of the normal production and operation has been unprecedented impact. In the face of the raging epidemic, the company quickly developed the "new coronavirus (2019-nCoV) nucleic acid test kit" during the Spring Festival, when the epidemic was the most serious, and donated the test reagent free of charge to domestic and foreign medical institutions for use. We have obtained the registration certificate of the new coronavirus test kit in China, and the new coronavirus test reagent products have been exported to more than 50 countries overseas. In addition, the company's chemiluminescence and blood gas products have been selected as the list of medical equipment recommended by the China Medical Equipment Association for the prevention and treatment of New Crown Pneumonia.
Reagent revenue in the reporting period accounted for 75.35% of the total revenue ratio, an increase of 214.20%. Among them, the new crown reagent revenue accounted for a large proportion, mainly in the first half of 2020, the new crown epidemic outbreak, the company launched the new crown test kit in a timely manner, in a number of provinces and municipalities across the country won the bid, and achieved good sales results. At the same time, the company's new crown detection kits have also obtained the certification of CE in Europe, TGA in Australia and ANVISA in Brazil, and are sold overseas, boosting the export business.
The combined revenue from instrument and agency business accounted for 4.67% of the total revenue ratio, representing a year-on-year increase of 295.24% and 215.62% respectively. Self-produced instruments and agency products are mainly related instrument platforms used in testing kits, and the increase in the volume of reagent business drove the volume of sales of instrument products.
It is worth mentioning that the company's test service revenue accounted for 19.26% of the total revenue ratio, an increase of 5105.90%. Mindray Biological wholly owned subsidiary Wuhan Mingzhi Medical Testing Laboratory Co., Ltd, reported a net profit of 30 million yuan, accounting for 14.99% of the company's total profit. For the performance of the big increase, Mindray said, mainly Wuhan Mingzhi Medical Laboratory Co., Ltd. as one of the designated Wuhan City, Wuhan City, the new crown nucleic acid testing organizations, in the new crown epidemic in Wuhan City, assumed the important work of the epidemic testing tasks, testing services revenue increased significantly.
Expected net profit in the first three quarters of the year-on-year growth of about 5-6 times
As Mind Biology said, by the impact of the epidemic, the company's operations in the first quarter of the impact, during the period of 28,551,900 yuan of operating income, a year-on-year decline of 39.36%; attributable to shareholders of the listed company's net profit of 1,944,500 yuan, a year-on-year decline of 87.92%. At that time, the new crown diagnostic products of Mindray biological orders decreased significantly year-on-year, and the new crown nucleic acid test kits developed during the epidemic have not yet been certified.
In the second quarter of the outbreak of new crown products and testing business volume, is expected to continue in the third quarter. Matilda Biological 23rd night performance forecast shows that the company expects January-September 2020 attributable to shareholders of listed companies net profit of 281 million yuan -351 million yuan, a year-on-year change of 513.33% -665.93%.
Mindray Bio judgment, at present, the situation of foreign epidemics is still severe, the domestic epidemic can not be ignored, it is expected that the third quarter of the new crown product business is still large; from the second quarter, the original product sales business gradually returned to normal, while optimizing the product structure, the formation of a multi-product line of testing and medical service solutions of the systematic product system, at the same time, the company is actively involved in the local hospital PCR laboratory
In addition, the company is actively involved in the construction of PCR laboratories in hospitals.
In addition, it is worth noting that Mindray is also increasing its in vitro diagnostic products for infectious diseases.
In the evening of August 3, Mindray announced that the company intends to invest in Mindray's Bio-technology Park (Phase I) project, which will be built on the basis of the originally planned fundraising projects - in vitro diagnostic reagent expansion project, mobile medical products construction project and R&D center construction project. On the basis of the original planned construction projects - in vitro diagnostic reagents expansion project, mobile medical products and R & D center construction project, self-funded investment of not more than 270 million yuan to invest in new construction and industrialization projects, and strive to build Mind Bio-technology Industrial Park as a professional, large-scale first-class in vitro diagnostic products industrial park in China, if you add the original investment projects, the Mind Bio-technology Industrial Park (Phase I) project the overall scale of investment of not more than 600 million yuan.